Cells - NT2
Commercial human cell line from testis embryonal carcinoma that can be differentiated with Retinoic Acid (RA) into neural cells.
ATCC Number: CRL-1973
Organism: Homo sapiens (human)
Designations: NTERA-2 cl.D1 [NT2/D1]
Tissue: embryonal carcinoma, malignant; testis; from metastatic site:lung
Depositors: P.W. Andrews
VirusSuscept: RA and HMBA TREATED CELLS: human cytomegalovirus (HCMV); human immunodeficiency virus (HIV-1, HTLV-III)
VirusResist: UNTREATED CELLS: human cytomegalovirus (HCMV); human immunodeficiency virus (HIV-1, HTLV-III)
FluidRenewal: every 2 to 3 days
SubCulturing: Subcultures are prepared by scraping.
Cells from confluent cultures (approximately 20 million cells per 75sq. cm.) are dislodged from the flask surface, aspirated and dispensed into new flasks.
Trypsin - EDTA dissociation can be used, but it is better to do so infrequently.
Cultures should be maintained at high density. Seed new flasks at a density of at least 5 X 10 exp6 viable cells per 75 sq. cm. flask.
Growth Properties: monolayer
Comments: The NTERA-2 cl.D1 cell line is a pluripotent human testicular embryonal carcinoma cell line derived by cloning the NTERA-2 cell line.The parental NTERA-2 lines was established in 1980 from a nude mouse xenograft of the Tera-2 cell line (see ATCC HTB-106).This clone differentiates along neuroectodermal lineages after exposure to retinoic acid (RA) or hexamethylene bisacetamide ((HMBA).The RA induced differentiation is characterized by glycolipid changes, appearance of neurons, and induction of homeobox (HOX) gene clusters.The cells exhibit high expression of N-myc oncogene activity.
To induce differentiation, the cells should be trypsinized and seeded at a density 1 X 10 exp6 cells per 75 sq. cm. in medium containing 0.01 mM trans-retinoic acid.Stock solutions of trans-retinoic acid (10 mM, dissolved in DMSO) should be stored frozen (preferably under a nitrogen atmosphere).
ATCC medium: Dulbecco's modified Eagle's medium with 4.5 g/L glucose,
90%; fetal bovine serum, 10%
Price Code: J
Biosafety Level: 1
Revised: Dec 31, 1997
<pubmed>1578271</pubmed> <pubmed>8411264</pubmed> <pubmed>3297853</pubmed> <pubmed>3326883</pubmed> <pubmed>10337488</pubmed> <pubmed></pubmed>